Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and .
DIACCURATEJanuary 12, 2021 GMT
Dr. Dominique BRIDON leads the new entity
DIACCURATE is now developing 3 programs in cancer and immunotherapy
DIACCURATE will be initiating a first clinical trial by early 2022
Paris, France, January 12, 2021
By acquiring BIOKINESIS, a French biotech that develops the very first anticancer compound targeting the Golgi apparatus, DIACCURATE comforts its “sole-in-class” therapeutic strategy in oncology and immunotherapy. The company is developing a new generation of drug candidates which relies on novel mechanisms of action and untapped cellular and subcellular compartments. Initial data already suggest that this highly innovative approach could help to improve resitance to cancer progression and extend the benefits of immunotherapy to more indications and pati